Rituximab dose-escalation trial in chronic lymphocytic leukemia.
By S. O'brien, H. Kantarjian, D. Thomas, F. Giles, E. Freireich, J. Cortes, S. Lerner, M. Keating. Journal of Clinical Oncology, 2001
626 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/2dbaca7762ad378429176735abf1334c7d98e7ff
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. (2005, background): “Rituximab had limited activity in previously treated patients with CLL, with a partial response rate of 10% to 15% at conventional doses.(11,12) Subsequent studies have shown that more intensive dose regimens can increase the OR rate in previously treated CLL patients to 40% to 75%,(12,13) and highe”
- Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. (2004, neutral): “Bone marrow infiltration, involved only, % 25 (1-90) 30 (4-90) 16 (5-90)”
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. (2002, neutral): “Improvement in WHO PS 8/20 (40) 9/49 (18) 17/69 (25)”
- Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (2014, neutral): “Renal 104 (44) 45 (38) 111 (48) 45 (38) 137 (41) 145 (44)”
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia (2014, neutral): “ALT or AST elevation 38 (35) 6 (5) 20 (19) 1 (1)”
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). (2003, neutral): “Induction CR 33 (20-46) 15 (5-25) Induction CR PR 90 (82-98) 77 (66-89) Consolidation PR to CR* 10 (2-18) 22 (13-36) Overall CR 47 (33-61) 28 (16-40) Overall PR CR 90 (82-98) 77 (66-89)”